Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset.
Maria Lizzio
Marco
M
Peluso
Giusy
G
Zoli
Angelo
A
Gremese
Elisa
E
Tolusso
Barbara
B
Ferraccioli
GianFranco
G
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D010352:Patient Dropouts; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001323:Autoantibodies; D015415:Biomarkers; D000069285:Infliximab